雍禾醫療(02279.HK)公開發售獲超額認購160.06倍 預計12月13日掛牌上市
格隆匯12月10日丨雍禾醫療(02279.HK)發佈公吿,公司全球發售9442.4萬股股份,其中香港發售股份4721.2萬股,國際發售股份4721.2萬股,另有15%超額配股權;發售價每股發售股份15.80港元,每手買賣單位500股;摩根士丹利及中金公司為聯席保薦人;預期股份將於2021年12月13日於聯交所主板掛牌上市。
香港發售股份已獲非常大幅超額認購。公司已接獲合共81,126份有效申請,認購合共15.11億股香港發售股份,相當於根據香港公開發售初步可供認購的香港發售股份總數約160.06倍。根據國際發售初步提呈發售的發售股份較根據國際發售初步可供認購的合共8498.1萬股國際發售股份獲超額認購約8.39倍。按發售價每股15.80港元計算,根據基石投資協議,基石投資者將獲分配合共4721.2萬股發售股份。
按發售價每股15.80港元計算,假設超額配股權未獲行使,公司將收取的全球發售所得款項淨額估計約為13.567億港元。公司擬將全球發售所得款項淨額約42.1%用於為中國境內網絡的現有植髮醫療機構進行擴充和升級;約17.5%將用於為產品及服務創新提供資金;約9.7%將用作投資於研發,以前沿技術提升我們的服務體系;約23.4%將用作在中國整合行業資源以提升品牌知名度;約1.6%將用作結清集團就於2021年5月收購顯赫植髮應付關聯方新絲域的收購代價的未償還結餘;及約5.7%將用作營運資金及一般企業用途。倘超額配股權獲悉數行使,公司將就因超額配股權獲行使而將予發行及配發的1416.35萬股額外發售股份收取額外所得款項淨額約2.137億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.